evidence table

Coenzyme Q10 Blood Pressure Meta-Analysis Evidence Table

Structured evidence table for Coenzyme Q10 Blood Pressure Meta-Analysis, generated from 2 reusable source documents in the Migaku knowledge base.

topicclaimevidence levelcitationsource
Coenzyme Q10 Blood Pressure Meta-AnalysisImportantly, while elevated intraocular pressure (IOP) is a well-established risk factor and the only available treatment target, it is neither necessary nor sufficient for the development of glaucoma, as evidenced by the existence of normal-tension glaucoma and the observation that many patients continue to progress despite achieving target IOP levels.3Hui Flora (2026)Vitamins and nutraceuticals in glaucoma research
Coenzyme Q10 Blood Pressure Meta-AnalysisIt is estimated that the number of individuals affected by glaucoma will continue to rise, with substantial socioeconomic impact due to vision loss and associated disability.Age is the most prominent risk factor, but genetic predisposition, vascular dysregulation, and systemic metabolic dysfunction have also been implicated in disease susceptibility and progression.3Hui Flora (2026)Vitamins and nutraceuticals in glaucoma research
Coenzyme Q10 Blood Pressure Meta-AnalysisStudies suggest that up to 28% of retinal ganglion cells may be lost before early visual field defects become apparent.Advances in imaging, home-based visual field monitoring, and artificial intelligence-assisted analysis are being developed to improve early detection and risk stratification, but challenges remain in predicting individual disease trajectories.3Hui Flora (2026)Vitamins and nutraceuticals in glaucoma research
Coenzyme Q10 Blood Pressure Meta-Analysis1 2 , Glaucoma is a common neurodegenerative disease characterized by the degeneration of retinal ganglion cells and their axons, leading to characteristic structural changes at the optic nerve head and corresponding visual field loss.3Hui Flora (2026)Vitamins and nutraceuticals in glaucoma research
Coenzyme Q10 Blood Pressure Meta-AnalysisDespite major advancements in pharmacotherapies and interventional cardiology, substantial residual risk persists among patients with established disease ().3Wu Xun (2026)Advances in cardiovascular supplementation: mechanisms, efficacy, and clinical perspectives
Coenzyme Q10 Blood Pressure Meta-AnalysisAdditionally, many nutraceuticals are perceived to possess favorable safety and tolerability profiles compared to conventional medications, making them attractive for long-term risk reduction ().3Wu Xun (2026)Advances in cardiovascular supplementation: mechanisms, efficacy, and clinical perspectives
Coenzyme Q10 Blood Pressure Meta-AnalysisBanach et al., 2018 Cicero et al., 2017 Sesso et al., 2008 However, the field is marked by heterogeneous and sometimes contradictory evidence.3Wu Xun (2026)Advances in cardiovascular supplementation: mechanisms, efficacy, and clinical perspectives
Coenzyme Q10 Blood Pressure Meta-AnalysisRoth et al., 2020 Ganda et al., 2018 Visseren et al., 2021 Cardiovascular disease (CVD) is the leading cause of mortality worldwide, accounting for nearly one-third of global deaths each year ().3Wu Xun (2026)Advances in cardiovascular supplementation: mechanisms, efficacy, and clinical perspectives
topicCoenzyme Q10 Blood Pressure Meta-Analysis
claimImportantly, while elevated intraocular pressure (IOP) is a well-established risk factor and the only available treatment target, it is neither necessary nor sufficient for the development of glaucoma, as evidenced by the existence of normal-tension glaucoma and the observation that many patients continue to progress despite achieving target IOP levels.
evidence level3
citationHui Flora (2026)
sourceVitamins and nutraceuticals in glaucoma research
topicCoenzyme Q10 Blood Pressure Meta-Analysis
claimIt is estimated that the number of individuals affected by glaucoma will continue to rise, with substantial socioeconomic impact due to vision loss and associated disability.Age is the most prominent risk factor, but genetic predisposition, vascular dysregulation, and systemic metabolic dysfunction have also been implicated in disease susceptibility and progression.
evidence level3
citationHui Flora (2026)
sourceVitamins and nutraceuticals in glaucoma research
topicCoenzyme Q10 Blood Pressure Meta-Analysis
claimStudies suggest that up to 28% of retinal ganglion cells may be lost before early visual field defects become apparent.Advances in imaging, home-based visual field monitoring, and artificial intelligence-assisted analysis are being developed to improve early detection and risk stratification, but challenges remain in predicting individual disease trajectories.
evidence level3
citationHui Flora (2026)
sourceVitamins and nutraceuticals in glaucoma research
topicCoenzyme Q10 Blood Pressure Meta-Analysis
claim1 2 , Glaucoma is a common neurodegenerative disease characterized by the degeneration of retinal ganglion cells and their axons, leading to characteristic structural changes at the optic nerve head and corresponding visual field loss.
evidence level3
citationHui Flora (2026)
sourceVitamins and nutraceuticals in glaucoma research
topicCoenzyme Q10 Blood Pressure Meta-Analysis
claimDespite major advancements in pharmacotherapies and interventional cardiology, substantial residual risk persists among patients with established disease ().
evidence level3
citationWu Xun (2026)
sourceAdvances in cardiovascular supplementation: mechanisms, efficacy, and clinical perspectives
topicCoenzyme Q10 Blood Pressure Meta-Analysis
claimAdditionally, many nutraceuticals are perceived to possess favorable safety and tolerability profiles compared to conventional medications, making them attractive for long-term risk reduction ().
evidence level3
citationWu Xun (2026)
sourceAdvances in cardiovascular supplementation: mechanisms, efficacy, and clinical perspectives
topicCoenzyme Q10 Blood Pressure Meta-Analysis
claimBanach et al., 2018 Cicero et al., 2017 Sesso et al., 2008 However, the field is marked by heterogeneous and sometimes contradictory evidence.
evidence level3
citationWu Xun (2026)
sourceAdvances in cardiovascular supplementation: mechanisms, efficacy, and clinical perspectives
topicCoenzyme Q10 Blood Pressure Meta-Analysis
claimRoth et al., 2020 Ganda et al., 2018 Visseren et al., 2021 Cardiovascular disease (CVD) is the leading cause of mortality worldwide, accounting for nearly one-third of global deaths each year ().
evidence level3
citationWu Xun (2026)
sourceAdvances in cardiovascular supplementation: mechanisms, efficacy, and clinical perspectives

Learn next

Related evidence and supplement guides

SupplementCoenzyme Q10 (CoQ10)A coenzyme essential for mitochondrial ATP energy production, supporting heart health and cellul...SupplementCoQ10 (Ubiquinol)Mitochondrial cofactor that declines with age and statin use — supports cardiac energy, fertilit...SupplementBerberinePlant alkaloid with clinical evidence rivalling metformin for blood glucose control and lipid ma...GuideCoenzyme Q10 Inflammation Meta-analysis: What the Evidence SaysCoenzyme Q10 Inflammation Meta-analysis has 2 source documents in the current Migaku evidence da...GuideOmega-3 Blood Pressure Meta-analysis: What the Evidence SaysOmega-3 Blood Pressure Meta-analysis has 2 source documents in the current Migaku evidence datab...GuideOlive Leaf Extract Blood Pressure Meta-analysis: What the Evidence SaysOlive Leaf Extract Blood Pressure Meta-analysis has 1 source documents in the current Migaku evi...GuidePolicosanol Blood Pressure Meta-analysis: What the Evidence SaysPolicosanol Blood Pressure Meta-analysis has 2 source documents in the current Migaku evidence d...CompareCoenzyme Q10 (Ubiquinone) vs UbiquinolUbiquinone is the traditional, oxidized form of CoQ10. Ubiquinol is the fully reduced, active an...

Source documents

  1. Vitamins and nutraceuticals in glaucoma research
  2. Advances in cardiovascular supplementation: mechanisms, efficacy, and clinical perspectives